Matrix Metalloproteinase Inhibitors: Applications in Oncology
- 1 November 1999
- journal article
- review article
- Published by Springer Nature in Investigational New Drugs
- Vol. 17 (4) , 387-399
- https://doi.org/10.1023/a:1006386406584
Abstract
Matrix metalloproteinases (MMP) are a group of zinc dependentenzymes which include the interstitial collagenases, stromelysins,gelatinases and membrane-type metalloproteinases. They are involvedin the remodelling and turnover of the extracellular matrixproteins. They play a role in wound healing and the pathogenesis ofarthritis. In malignancies they play a role in tumor invasion,metastasis and angiogenesis. A number of synthetic matrixmetalloproteinase inhibitors (MMPIs) have been developed forclinical use. In preclinical tumor models they have shown promisingactivity in achievinginhibition of MMPs and reducing tumor growth and metastatic spread.Some have also shown additive or synergistic effects with cytotoxicagents. Phase I and II studies in human subjects have defined themain side effects of these agents as beingmusculoskeletal pains or arthralgias. As they are cytostatic agentsrather than cytotoxic in activity conventional measurements ofradiological response for assessment are not applicable in trials.Biological activity has been demonstrated in certain cancers by theeffects on levels of tumor markers as surrogate markers of tumorresponse and also by a fibrotic stromal reaction seen in tumortissue. Newer agents have been developed withselective inhibition of certain MMPs in an attempt to reduce theside effects. A number of phase III human clinical trialsevaluating MMPs are being carried out at present but onlyone has been formally reported so far. This study suggested thatmarimastat had no survival advantage when compared to chemotherapywith gemcitabine in advanced pancreatic carcinoma. Current trialsare assessing efficacy of MMPIs in maintenance of remission afterother modalities of therapy or in combination with cytotoxicagents. MMPs have also been demonstrated to play an important rolein the articular cartilage destruction seen in both rheumatoidarthritis and osteoarthritis. The use of MMPIs in both exvivoand in vivomodels have shown promising resultsand trials are in process to assess their potential role in thecontrol of articular destruction. The true therapeutic role ofMMPIs await the results of these randomized studies.Keywords
This publication has 56 references indexed in Scilit:
- Head and Neck CancerAnnals of Oncology, 1998
- Results of single and repeat dose studies of the oral matrix metalloproteinase inhibitor marimastat in healthy male volunteersBritish Journal of Clinical Pharmacology, 1998
- HLA markers and prediction of clinical course and outcome in rheumatoid arthritisArthritis & Rheumatism, 1997
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- Experimental and clinical studies on the use of matrix metalloproteinase inhibitors for the treatment of cancerEuropean Journal Of Cancer, 1996
- Correlation between stromelysin‐3 mRNA level and outcome of human breast cancerInternational Journal of Cancer, 1994
- Inhibition of the metastatic spread and growth of B16‐BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitorInternational Journal of Cancer, 1994
- Inhibition of angiogenesis by tissue inhibitor of metalloproteinaseJournal of Cellular Physiology, 1994
- Detection of Stromelysin and Collagenase in Synovial Fluid From Patients with Rheumatoid Arthritis and Posttraumatic Knee InjuryArthritis & Rheumatism, 1992
- Metastatic potential correlates with enzymatic degradation of basement membrane collagenNature, 1980